ATS Corporation outlined its margin-expansion plan on Sept. 10 at the Jefferies Global Industrials Conference, targeting a return to a 15% EBIT margin with potential upside to the high teens over time.
The company, founded in 1978 and headquartered in Canada, reported approximately CAD 3 billion in annual revenue. It trades around CAD 26.55, down 0.67% from a prior close of CAD 26.72, within a 52-week range of CAD 25.59 to CAD 49.48.
About half of ATS revenue now comes from the life sciences segment, which spans discovery, development and production including radiopharmaceuticals, medical devices, auto-injectors, contact lenses and automated pharmacy systems. Roughly 80% of the company's backlog sits in highly regulated industries. Service revenue accounts for about one-third of the business, and in mature operations aftermarket entitlement can reach 40% to 50% of revenue.
Management said margin improvement will come from three sources, each contributing roughly 25% to 50%: self-help and fixed-cost transformation, aftermarket services growth, and maturation of the ATS business model alongside supply-chain optimization.
The fixed-cost transformation program, which interim CFO Anne Cybulski — a 17-year ATS veteran — helped design, follows a "do no harm" approach for customer-facing operations. The plan focuses on de-investment in over-invested areas, capacity and site rationalization notably in Europe and the Americas where industrial automation and life sciences teams share skill sets, and applying a cash return-on-invested-capital framework across decentralized business units.
ATS has shifted its portfolio away from older transportation and internal-combination engine OEM sub-markets toward regulated sectors including life sciences, food and beverage, energy and consumer/industrial. The food and beverage segment is expected to post stable GDP-plus-1%-to-2% growth, while life sciences should see high-single-digit organic growth.
The company pointed to its 2019 acquisition of Italy-based Comecer as a key radiopharmaceutical automation play spanning diagnostic PET scanning through therapeutic radioisotope treatments. Group Executive for Life Sciences Sarah Moore, who joined ATS roughly 10 months ago after 16 years at Siemens and seven at Danaher, was among the speakers. CEO Doug, also a Danaher alumnus, was noted during the session moderated by Jefferies' Steve Gavales.
On technology, management emphasized that ATS combines proprietary machines, application scientists, digital twins and digital solutions to handle ecosystem interoperability rather than relying on software or AI alone.
